Will you switch? asks Dr. Paul Sax in his blog
HIV and ID Observations.
The FDA has just approved a generic formulation of abacavir in 300-mg tablets, which are approved for twice-daily dosing. Notably, the approval does not extend to the coformulated once-daily abacavir/3TC tablet. Will you switch your patients to generic abacavir? Vote here.